BioSpaceOriginal article
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
Phase 1negativeNegative
AI Analysis
Summary
Bristol Myers Squibb has terminated a targeted degrader-antibody conjugate program acquired from Orum Therapeutics in 2023 following a review of Phase 1 data. The acquisition had included $100 million upfront plus up to $80 million in milestone payments.
Clinical Trial Data
Phase
1
Primary Endpoint
Not Met
Outcome Details
BMS scrapped the targeted degrader-antibody conjugate after reviewing Phase 1 data
Importance:5/10
Sentiment:
-0.80
phase_1_failureprogram_terminationacquisitiondegraderantibody_conjugate
Related Companies
Read the original article
Published by BioSpace on September 18, 2026 12:19 PM